2026 Global: Cardiac Safety Services Market-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Safety Services Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac safety services market by geography and historical trend. The scope of the report extends to sizing of the cardiac safety services market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Laboratory Corporation of America Holdings (LabCorp) leads the cardiac safety services market, holding the largest share in 2022 through its comprehensive clinical laboratory services and drug development support for pharmaceuticals and biotech firms. Medpace follows as a key player, offering integrated solutions across cardiology, oncology, and other divisions, including clinical trial management, pharmacovigilance, and core laboratory services from Phase I to IV. Koninklijke Philips N.V. excels in diagnostic technologies like ECG monitoring and AI-driven cardiac imaging, bolstered by acquisitions such as Cardiologs in 2021 to enhance its cardiology portfolio. Clario, formed from the 2021 ERT-Bioclinica merger, dominates with over 19,000 trials and 870 regulatory approvals, providing endpoint technology for cardiovascular drug safety across 100+ countries. Eurofins Scientific provides specialized ECG assessments, QT interval analysis, and cardiac risk evaluations, expanding via the 2022 acquisition of Genetic Lab Co. to strengthen diagnostics and drug discovery.
IQVIA delivers full-spectrum services including ECG core labs and QT analysis, ensuring regulatory compliance in drug development, with strategic moves like acquiring Q2 Solutions shares in 2021. PPD Inc., now part of Thermo Fisher, specializes in ECG evaluations and QT/QTc assessments for clinical trials, supported by a 2021 investment expanding its global operations in North America, Europe, and Asia-Pacific. Charles River Laboratories and WuXi AppTec contribute through preclinical and early-phase cardiac safety testing, with WuXi focusing on bioanalytical and contract research services amid market growth projections. Celerion stands out for over 40 years in early-phase studies, completing 60+ Thorough QT trials with specialized facilities for cardiovascular liability evaluation. ICON Plc and SGS S.A. round out the top tier, offering global CRO services like biometric analysis and regulatory support, with ICON emphasizing integrated trial management and SGS providing broad safety assessments.
These ten companies—LabCorp, Medpace, Philips, Clario, Eurofins, IQVIA, PPD, Charles River, WuXi AppTec, and Celerion—collectively drive a consolidated market projected to reach USD 1.9-2.4 billion by 2030-2032 at CAGRs of 10.8-15.4%, fueled by rising cardiovascular drug trials and regulatory demands for QT and ECG monitoring. Their innovations, such as AI-enhanced telemetry and hiPSC models from players like Ncardia (an emerging contender), address complex needs in oncology and gene therapies, ensuring patient safety and expedited approvals. Strategic partnerships and M&A, including Philips' infrastructure investments and Clario's AI ECG scoring, solidify their leadership amid North America's 41% revenue dominance. This competitive landscape prioritizes specialized standalone services alongside integrated CRO offerings, enabling pharma sponsors to navigate FDA benchmarks like CiPA paradigms effectively.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac safety services market by geography and historical trend. The scope of the report extends to sizing of the cardiac safety services market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Laboratory Corporation of America Holdings (LabCorp) leads the cardiac safety services market, holding the largest share in 2022 through its comprehensive clinical laboratory services and drug development support for pharmaceuticals and biotech firms. Medpace follows as a key player, offering integrated solutions across cardiology, oncology, and other divisions, including clinical trial management, pharmacovigilance, and core laboratory services from Phase I to IV. Koninklijke Philips N.V. excels in diagnostic technologies like ECG monitoring and AI-driven cardiac imaging, bolstered by acquisitions such as Cardiologs in 2021 to enhance its cardiology portfolio. Clario, formed from the 2021 ERT-Bioclinica merger, dominates with over 19,000 trials and 870 regulatory approvals, providing endpoint technology for cardiovascular drug safety across 100+ countries. Eurofins Scientific provides specialized ECG assessments, QT interval analysis, and cardiac risk evaluations, expanding via the 2022 acquisition of Genetic Lab Co. to strengthen diagnostics and drug discovery.
IQVIA delivers full-spectrum services including ECG core labs and QT analysis, ensuring regulatory compliance in drug development, with strategic moves like acquiring Q2 Solutions shares in 2021. PPD Inc., now part of Thermo Fisher, specializes in ECG evaluations and QT/QTc assessments for clinical trials, supported by a 2021 investment expanding its global operations in North America, Europe, and Asia-Pacific. Charles River Laboratories and WuXi AppTec contribute through preclinical and early-phase cardiac safety testing, with WuXi focusing on bioanalytical and contract research services amid market growth projections. Celerion stands out for over 40 years in early-phase studies, completing 60+ Thorough QT trials with specialized facilities for cardiovascular liability evaluation. ICON Plc and SGS S.A. round out the top tier, offering global CRO services like biometric analysis and regulatory support, with ICON emphasizing integrated trial management and SGS providing broad safety assessments.
These ten companies—LabCorp, Medpace, Philips, Clario, Eurofins, IQVIA, PPD, Charles River, WuXi AppTec, and Celerion—collectively drive a consolidated market projected to reach USD 1.9-2.4 billion by 2030-2032 at CAGRs of 10.8-15.4%, fueled by rising cardiovascular drug trials and regulatory demands for QT and ECG monitoring. Their innovations, such as AI-enhanced telemetry and hiPSC models from players like Ncardia (an emerging contender), address complex needs in oncology and gene therapies, ensuring patient safety and expedited approvals. Strategic partnerships and M&A, including Philips' infrastructure investments and Clario's AI ECG scoring, solidify their leadership amid North America's 41% revenue dominance. This competitive landscape prioritizes specialized standalone services alongside integrated CRO offerings, enabling pharma sponsors to navigate FDA benchmarks like CiPA paradigms effectively.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.